Sources

  1. Hrishikesh, Vyawahare, and Shinde Pranaykumar. “Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment.” Cureus 14.9 (2022).
  2. Centers for Disease Control and Prevention. “VEHSS Modeled Estimates: Age-Related Macular Degeneration (AMD).” Vision and Eye Health Surveillance System (VEHSS), National Center for Chronic Disease Prevention and Health Promotion, 15 May 2024, www.cdc.gov/vision-health-data/prevalence-estimates/amd-prevalence.html
  3. Hobbs, Samuel D., Koushik Tripathy, and Kristine Pierce. “Wet age-related macular degeneration (AMD).” StatPearls [Internet]. StatPearls Publishing, 2024.
  4. Clemens, Christoph R., Nicole Eter, and Florian Alten. “Current perspectives on type 3 macular neovascularization due to age-related macular degeneration.” Ophthalmologica247.2 (2024): 73-84.
  5. Stahl, Andreas. “The Diagnosis and Treatment of Age-Related Macular Degeneration.” Deutsches Arzteblatt international vol. 117,29-30 (2020): 513-520. doi:10.3238/arztebl.2020.0513
  6. Silva, Rufino, and João Pedro Marques. “Neovascular Phenotypes: Retinal Angiomatous Proliferation (RAP) or Type 3 Neovascularization.” AMD Book, GER Group, updated July 2017, www.amdbook.org/content/neovascular–phenotypesrap-retinal–angiomatous-proliferation
  7. Kaufman, Stephen R., et al. “Genetics and Age-Related Eye Disease Study Formulation Interaction in Neovascular Age-Related Macular Degeneration.” Journal of Vitreoretinal Diseases, vol. 5, no. 1, 19 Aug. 2020, pp. 46–52. PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC9976046/.
  8. Lavine, Jeremy A., et al. “Attenuation of Choroidal Neovascularization by β2-Adrenergic Receptor Antagonism.” JAMA Ophthalmology, vol. 131, no. 3, Mar. 2013, pp. 376–382. PubMed Central, https://ncbi.nlm.nih.gov/articles/PMC3652586/.